封面
市場調查報告書
商品編碼
1600977

注射市場:按分子類型、藥物類別、注射途徑和應用分類 - 2025-2030 年全球預測

Injectable Drugs Market by Molecule Type (Large Molecule, Small Molecule), Drug Class (Blood Factors, Cytokines, Immunoglobulin), Injection Routes, Application - Global Forecast 2025-2030

出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年注射劑市值為5633億美元,預計到2024年將達到6170.4億美元,複合年成長率為9.86%,到2030年將達到10885.5億美元。

市場區隔是製藥業的動態部分,涵蓋透過針頭方法管理的各種產品,例如疫苗、生技藥品、胰島素和單株抗體。注射劑的需求是將藥物快速輸送到血液中,確保快速起效,這對於糖尿病、癌症和自體免疫疾病等急性疾病以及需要精確劑量的長期疾病非常重要。應用涵蓋腫瘤學、內分泌學和神經學等治療領域,最終用途包括醫院、診所、居家醫療機構,有時也用於透過筆式注射器或自動注射器自我給藥。

主要市場統計
基準年[2023] 5633億美元
預測年份 [2024] 6170.4億美元
預測年份 [2030] 1,088,550 百萬美元
複合年成長率(%) 9.86%

該市場主要由慢性病患病率上升、生技藥品的進步以及疫苗需求的增加所推動。人口老化和不斷擴大的醫療基礎設施將進一步支持成長。新的商機在於生物相似藥、無針輸送系統和預填充式注射器,這些可以提高病患的依從性和安全性。此外,個人化醫療正在不斷發展,與數位健康解決方案整合的智慧注射器的採用也在增加。然而,市場面臨著諸如高成本、嚴格的監管要求以及注射劑的潛在副作用等挑戰,這些副作用可能會影響合規性和可接受性。來自替代藥物輸送的競爭和對針頭治療的猶豫也構成了障礙。

為了發展您的業務,您可以將創新重點放在開發具有成本效益的生產技術、提高藥物配方的穩定性以及改進輸送系統以最大限度地減少注射相關的疼痛和焦慮。將物聯網和人工智慧融入設備中可以即時監控和追蹤依從性,從而改善患者的治療效果。市場競爭仍然很激烈,需要持續的研發投資來應對這些挑戰並利用成長機會。鼓勵公司建立策略夥伴關係和聯盟,以擴大其產品組合和市場佔有率。駕馭這個複雜的市場需要採取靈活且富有遠見的方法,深入研究尖端的藥物傳輸技術和整體患者照護解決方案。

市場動態:揭示快速發展的注射劑市場的關鍵市場洞察

供需的動態交互作用正在改變注射藥物市場。透過了解這些不斷變化的市場動態,公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險,同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 慢性病負擔增加
    • 擴大預填充和自我治療藥物的使用
    • 藥物傳遞在癌症治療的持續普及
  • 市場限制因素
    • 增加產品召回
  • 市場機會
    • 注射劑的快速開發和核准
    • 注射劑製造商之間的策略聯盟
  • 市場挑戰
    • 製造流程複雜,注射劑供不應求

波特五力:駕馭注射藥品市場的策略工具

波特的五力框架是了解注射市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢,解決弱點並避免潛在的挑戰,從而確保更強大的市場地位。

PESTLE分析:了解注射藥品市場的外部影響

外部宏觀環境因素在塑造注射劑市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素,公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化,並為他們做出積極主動的決策做好準備。

市場佔有率分析:了解注射藥品市場競爭狀況

對注射劑市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢,為供應商提供了製定策略決策所需的洞察力,使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣:注射劑市場供應商的績效評估

FPNV定位矩陣是評估注射劑市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商,從而做出符合其目標的明智決策。四個象限清楚且準確地分類供應商,幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析:

1. 市場滲透率:對當前市場環境的詳細回顧,包括行業主要企業的大量資料。

2. 市場開拓:辨識新興市場的成長機會,評估現有領域的擴張潛力,並提供未來成長的策略藍圖。

3. 市場多元化:分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報:徹底分析競爭格局,檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新:重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題,以幫助相關人員做出明智的決策:

1.目前的市場規模和未來的成長預測是多少?

2. 哪些產品、區隔市場和地區提供最佳投資機會?

3.塑造市場的主要技術趨勢和監管影響是什麼?

4.主要廠商的市場佔有率和競爭地位如何?

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼?

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病負擔增加
      • 預填充藥物和自行注射藥物的使用增加
      • 受控藥物傳輸載體在癌症治療中的持續實踐
    • 抑制因素
      • 產品回收數量增加
    • 機會
      • 注射劑的快速開發和核准
      • 注射劑製造商之間的策略聯盟
    • 任務
      • 製造流程複雜,注射劑短缺
  • 市場區隔分析
    • 藥物類別:細胞激素注射蛋白對細胞訊號傳導的偏好增加
    • 應用:擴大注射劑在自體免疫疾病治療的應用
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境
  • 客戶客製化

第6章注射劑市場:依分子類型

  • 高分子
  • 小分子

第7章注射劑市場:依藥物類別

  • 血液因素
  • 細胞激素
  • 免疫球蛋白
  • 胰島素
  • 單株抗體
  • 肽激素

第8章注射劑市場:依注射途徑

  • 肌肉注射
  • 椎管內的
  • 靜脈
  • 皮下的

第9章注射劑市場:依應用分類

  • 自體免疫疾病
  • 心血管疾病
  • 感染疾病
  • 神經病學
  • 腫瘤學
  • 疼痛

第10章美洲注射劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太注射劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲注射市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣,2023
  • 競爭情境分析
    • Sun Pharma 與 Taro 宣布合併協議
    • Glenmark 在印度推出了流行的抗糖尿病藥物Liraglutide的生物相似藥。
    • 百時美施貴寶的Opdivo注射液達到腎癌臨床試驗的關鍵目標

公司名單

  • Fresenius Kabi AG
  • SCHOTT PHARMA AG & CO. KGAA
  • F. Hoffmann-La Roche Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Sanofi SA
  • Abbott Laboratories
  • Bristol-Myers Squibb Company
  • Viatris Inc.
  • AstraZeneca PLC
  • Gilead Sciences, Inc.
  • Daiichi Sankyo Co., Ltd.
  • Ferring BV
  • Cipla Limited
  • Merck & Co., Inc.
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • AbbVie Inc.
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Biogen Inc.
  • Eli Lilly and Company
  • Pfizer Inc.
  • EVER Neuro Pharma GmbH
  • Chiesi Farmaceutici SpA
  • Eagle Pharmaceuticals, Inc.
  • Novo Nordisk A/S
Product Code: MRR-742BD517FCA4

The Injectable Drugs Market was valued at USD 563.30 billion in 2023, expected to reach USD 617.04 billion in 2024, and is projected to grow at a CAGR of 9.86%, to USD 1,088.55 billion by 2030.

The injectable drugs market is a dynamic segment of the pharmaceuticals industry, encompassing a range of products administered by needle-based methods, including vaccines, biologics, insulin, and monoclonal antibodies, among others. The necessity of injectable drugs is underscored by their rapid delivery of medication into the bloodstream, ensuring quick onset of action, which is critical for acute conditions and long-term conditions requiring precise dosing such as diabetes, cancer, and autoimmune disorders. Applications extend to therapeutic areas like oncology, endocrinology, and neurology, with end-use spanning hospitals, clinics, home healthcare settings, and sometimes self-administration facilitated by pen injectors and auto-injectors.

KEY MARKET STATISTICS
Base Year [2023] USD 563.30 billion
Estimated Year [2024] USD 617.04 billion
Forecast Year [2030] USD 1,088.55 billion
CAGR (%) 9.86%

The market is primarily driven by the rising prevalence of chronic diseases, advancements in biologics, and increased demand for vaccines. Aging populations and expanding healthcare infrastructure further bolster growth. Emerging opportunities lie in biosimilars, needle-free delivery systems, and prefilled syringes that improve patient compliance and safety. Furthermore, personalized medicine is advancing, as is adoption of smart injectables with integrated digital health solutions. However, the market faces challenges such as high costs, stringent regulatory requirements, and potential side effects of injectable drugs that may affect compliance and acceptance. Competition from alternative drug delivery methods and hesitation over needle-based therapy also present hurdles.

For business growth, innovation could focus on developing cost-effective production technologies, improving drug formulation stability, and advancing delivery systems that minimize pain and anxiety associated with injections. Incorporating IoT and AI into devices can offer real-time monitoring and adherence tracking, thus enhancing patient outcomes. The market remains competitive and requires ongoing R&D investment to address these challenges and capitalize on growth opportunities. Companies are encouraged to form strategic partnerships and collaborations to expand their portfolios and market presence. Navigating this complex market will demand agility and a forward-thinking approach, delving into cutting-edge drug delivery technologies and holistic patient care solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Injectable Drugs Market

The Injectable Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising Burden of Chronic Diseases
    • Growing Use of Prefilled and Self-Injectable Drugs
    • Ongoing Practice of Controlled Drug Delivery Vehicles for Cancer Treatment
  • Market Restraints
    • Rise in Incidences of Product Recall
  • Market Opportunities
    • Rapid Developments and Approvals in Injectable Drugs
    • Strategic Alliances Among Manufacturers for Injectable Drugs
  • Market Challenges
    • Complex Manufacturing Process and Shortages of Injectable Drugs

Porter's Five Forces: A Strategic Tool for Navigating the Injectable Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Injectable Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Injectable Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Injectable Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Injectable Drugs Market

A detailed market share analysis in the Injectable Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Injectable Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Injectable Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Injectable Drugs Market, highlighting leading vendors and their innovative profiles. These include Fresenius Kabi AG, SCHOTT PHARMA AG & CO. KGAA, F. Hoffmann-La Roche Ltd., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Sanofi S.A., Abbott Laboratories, Bristol-Myers Squibb Company, Viatris Inc., AstraZeneca PLC, Gilead Sciences, Inc., Daiichi Sankyo Co., Ltd., Ferring B.V., Cipla Limited, Merck & Co., Inc., Baxter International Inc., Boehringer Ingelheim International GmbH, Novartis AG, AbbVie Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Eli Lilly and Company, Pfizer Inc., EVER Neuro Pharma GmbH, Chiesi Farmaceutici S.p.A., Eagle Pharmaceuticals, Inc., and Novo Nordisk A/S.

Market Segmentation & Coverage

This research report categorizes the Injectable Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Molecule Type, market is studied across Large Molecule and Small Molecule.
  • Based on Drug Class, market is studied across Blood Factors, Cytokines, Immunoglobulin, Insulin, Monoclonal Antibodies, and Peptide Hormone.
  • Based on Injection Routes, market is studied across Intramuscular, Intraocular, Intrathecal, Intravenous, and Subcutaneous.
  • Based on Application, market is studied across Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, Neurology, Oncology, and Pain.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Burden of Chronic Diseases
      • 5.1.1.2. Growing Use of Prefilled and Self-Injectable Drugs
      • 5.1.1.3. Ongoing Practice of Controlled Drug Delivery Vehicles for Cancer Treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Rise in Incidences of Product Recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Rapid Developments and Approvals in Injectable Drugs
      • 5.1.3.2. Strategic Alliances Among Manufacturers for Injectable Drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Complex Manufacturing Process and Shortages of Injectable Drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Increasing preference for cytokines injectable protein for cell signaling
    • 5.2.2. Application: Growing application of injectable drugs for treating autoimmune diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Injectable Drugs Market, by Molecule Type

  • 6.1. Introduction
  • 6.2. Large Molecule
  • 6.3. Small Molecule

7. Injectable Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Blood Factors
  • 7.3. Cytokines
  • 7.4. Immunoglobulin
  • 7.5. Insulin
  • 7.6. Monoclonal Antibodies
  • 7.7. Peptide Hormone

8. Injectable Drugs Market, by Injection Routes

  • 8.1. Introduction
  • 8.2. Intramuscular
  • 8.3. Intraocular
  • 8.4. Intrathecal
  • 8.5. Intravenous
  • 8.6. Subcutaneous

9. Injectable Drugs Market, by Application

  • 9.1. Introduction
  • 9.2. Autoimmune Diseases
  • 9.3. Cardiovascular Diseases
  • 9.4. Infectious Diseases
  • 9.5. Neurology
  • 9.6. Oncology
  • 9.7. Pain

10. Americas Injectable Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Injectable Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Injectable Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Sun Pharma and Taro announce merger agreement
    • 13.3.2. Glenmark launched Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India
    • 13.3.3. Bristol Myers' injectable form of Opdivo meets main goal in kidney cancer trial

Companies Mentioned

  • 1. Fresenius Kabi AG
  • 2. SCHOTT PHARMA AG & CO. KGAA
  • 3. F. Hoffmann-La Roche Ltd.
  • 4. Dr. Reddy's Laboratories Ltd.
  • 5. Sun Pharmaceutical Industries Ltd.
  • 6. GlaxoSmithKline PLC
  • 7. Johnson & Johnson Services, Inc.
  • 8. Sanofi S.A.
  • 9. Abbott Laboratories
  • 10. Bristol-Myers Squibb Company
  • 11. Viatris Inc.
  • 12. AstraZeneca PLC
  • 13. Gilead Sciences, Inc.
  • 14. Daiichi Sankyo Co., Ltd.
  • 15. Ferring B.V.
  • 16. Cipla Limited
  • 17. Merck & Co., Inc.
  • 18. Baxter International Inc.
  • 19. Boehringer Ingelheim International GmbH
  • 20. Novartis AG
  • 21. AbbVie Inc.
  • 22. Amgen Inc.
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. Biogen Inc.
  • 25. Eli Lilly and Company
  • 26. Pfizer Inc.
  • 27. EVER Neuro Pharma GmbH
  • 28. Chiesi Farmaceutici S.p.A.
  • 29. Eagle Pharmaceuticals, Inc.
  • 30. Novo Nordisk A/S

LIST OF FIGURES

  • FIGURE 1. INJECTABLE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. INJECTABLE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. INJECTABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. INJECTABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INJECTABLE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INJECTABLE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY BLOOD FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY PEPTIDE HORMONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAOCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. INJECTABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 199. INJECTABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023